Thousands of women who used Depo-Provera now have legal claims against Pfizer in the depo class action lawsuit. The core allegation is that Pfizer failed to warn users that long-term use of the injectable contraceptive could cause meningioma brain tumors.
This is not a small case. As of 2026, litigation has grown into one of the largest pharmaceutical mass torts in federal court history.
In this guide, you’ll find everything you need to know. That includes who qualifies, what the case is about, how much settlements might pay, and how to file your own claim.
One statistic puts the stakes in sharp focus: a major French regulatory study found that women who used Depo-Provera for five or more years faced a risk of meningioma that was more than five times higher than non-users.
What Is the Depo Class Action Lawsuit?
The depo class action lawsuit refers to the ongoing wave of legal claims filed against Pfizer over its injectable contraceptive, Depo-Provera, which contains the synthetic hormone medroxyprogesterone acetate.
Plaintiffs allege that Pfizer knew, or should have known, that prolonged use of the drug could cause meningioma brain tumors. They say the company failed to disclose that risk clearly on the product label.
The legal theory is called “failure to warn.” It doesn’t require proving the drug doesn’t work. It requires proving the company hid a serious risk from the women taking it.
Most of these cases are being handled not as a traditional class action but as an MDL, which is a form of mass tort. The distinction matters and is covered later in this guide.
| Basic Case Facts | Details |
|---|---|
| Drug at Issue | Depo-Provera (medroxyprogesterone acetate) |
| Defendant | Pfizer Inc. |
| Core Allegation | Failure to warn of meningioma brain tumor risk |
| Legal Theory | Product liability, failure to warn |
| Court | Northern District of Illinois |
| Case Type | MDL mass tort (not traditional class action) |
Key Takeaway from This Section: The depo class action lawsuit is rooted in Pfizer’s alleged failure to disclose a known brain tumor risk to women using Depo-Provera long-term.
Depo-Provera Lawsuit 2026: Where Things Stand Right Now
In 2026, the Depo-Provera lawsuit is in an active and critical phase. Bellwether trials, which are early test cases used to gauge how juries respond to evidence, are being prepared in the Northern District of Illinois.
These trial results will shape how Pfizer approaches settlement negotiations. If early plaintiffs win large verdicts, Pfizer has strong financial incentives to settle the broader litigation quickly.
New cases are still being filed at a rapid pace in 2026. Attorneys estimate that tens of thousands of women may eventually be part of this litigation.
| 2026 Litigation Phase | Status |
|---|---|
| MDL Established | Active in Northern District of Illinois |
| Bellwether Selection | Underway |
| First Trials | Expected late 2026 or early 2027 |
| Settlement Talks | Early stages, no global deal announced |
| New Claims | Still being accepted |
The case received a significant boost in 2024 when the FDA updated the Depo-Provera label to include a warning about meningioma risk. That label change is now being used by plaintiffs as evidence that Pfizer had information it should have disclosed years earlier.
The Depo-Provera Brain Tumor Lawsuit Explained
The Depo-Provera brain tumor lawsuit is built on scientific evidence linking the drug’s active ingredient to meningioma, a type of tumor that grows on the membranes surrounding the brain and spinal cord.
Meningiomas are generally described as slow-growing. But they can cause serious neurological damage, vision problems, hearing loss, seizures, and in some cases, death.
Many plaintiffs had no idea their tumor was connected to their birth control. They used Depo-Provera for years, sometimes decades, before receiving a meningioma diagnosis.
The brain tumor claims allege that Pfizer’s failure to disclose the risk caused women to continue taking the drug without understanding what it could do to them.
Critical fact: Most meningioma tumors linked to Depo-Provera do not shrink on their own. Many require surgery, radiation, or both.
- Meningioma grows on brain/spinal cord membranes
- It can cause pressure damage to surrounding tissue
- Symptoms include headaches, vision changes, and hearing loss
- Treatment often requires surgery or radiation
- Many women received diagnoses years after stopping the drug
Key Takeaway: The brain tumor at the center of this lawsuit is meningioma, and many plaintiffs didn’t connect it to Depo-Provera until years after the damage was done.
Pfizer’s Role in the Depo-Provera Lawsuit
Pfizer is the primary defendant in the depo class action lawsuit because it is the manufacturer and distributor of Depo-Provera in the United States.
Pfizer acquired the rights to Depo-Provera through its purchase of Pharmacia and later through its control of the Upjohn division. The drug has been on the market in the U.S. since 1992.
Plaintiffs argue that Pfizer had access to scientific studies suggesting a hormone-meningioma link for many years before the FDA’s 2024 label update. The lawsuit alleges Pfizer prioritized sales over patient safety.
Pfizer has denied wrongdoing. The company’s legal team has argued that the existing label was adequate and that the scientific evidence is still being evaluated.
| Pfizer Timeline | Key Dates |
|---|---|
| FDA Approval of Depo-Provera | 1992 |
| Pfizer Acquires Pharmacia | 2003 |
| Major French Meningioma Study Published | 2023 |
| FDA Label Update Adding Meningioma Warning | 2024 |
| MDL Established in Illinois | 2024-2025 |
| Bellwether Trials Expected | Late 2026 |
Pfizer is one of the world’s largest pharmaceutical companies. That financial scale means it has substantial resources to fight litigation. But it also means it has the capacity to fund large settlements if the evidence turns strongly against it.
What Is the Depo-Provera Meningioma Lawsuit?
The Depo-Provera meningioma lawsuit is specifically the legal claim filed by women who used Depo-Provera and later received a meningioma diagnosis. Meningioma is the medical condition at the core of this entire case.
Not every Depo-Provera user is filing suit. The meningioma lawsuit is targeted specifically at women who developed this type of tumor, which plaintiffs trace directly to prolonged hormonal exposure from the drug.
Meningiomas connected to hormonal exposure are often referred to as “hormone-dependent” tumors. Research suggests that progesterone receptors in the brain may allow synthetic progestins like medroxyprogesterone acetate to accelerate tumor growth.
| Meningioma Basics | Facts |
|---|---|
| What it is | Tumor on brain/spinal cord membranes |
| Common Symptoms | Headaches, vision changes, seizures, weakness |
| Hormone Connection | Meningiomas express progesterone receptors |
| Drug Connection | MPA in Depo-Provera may bind to these receptors |
| Treatment | Surgery, radiation, or monitoring |
Women who had a meningioma removed surgically and later learned about the Depo-Provera connection are among the strongest candidates for legal claims.
Key Takeaway: The meningioma lawsuit is not a general dissatisfaction claim. It is a specific medical harm lawsuit tied to a diagnosed tumor condition.
Who Qualifies for the Depo-Provera Lawsuit?
You may qualify for the Depo-Provera lawsuit if you used Depo-Provera injections for at least one year and were later diagnosed with a meningioma brain tumor.
The core eligibility formula is straightforward: drug use plus medical diagnosis equals potential claim. But the details of your use history and diagnosis will shape how strong your claim is.
Women who used the drug for longer periods and received higher-grade meningioma diagnoses are likely to receive more attention from attorneys and potentially higher compensation.
General qualifications include:
- Received Depo-Provera injections (the injectable form, not Depo-SubQ)
- Used the drug for a minimum of approximately 12 months
- Received a medical diagnosis of meningioma
- Diagnosis occurred after beginning Depo-Provera use
- Meningioma required surgery, radiation, or ongoing treatment
Women who used the drug for five or more years are considered particularly strong candidates. The French study that anchors much of this litigation specifically looked at extended use patterns.
Depo-Provera Lawsuit Eligibility Requirements in Detail
The detailed eligibility requirements for the Depo-Provera lawsuit go beyond just having used the drug and getting a diagnosis.
Attorneys evaluating cases look at the timing, duration, and form of use. They also look at whether your meningioma was diagnosed by imaging or biopsy and whether you have medical records to support both.
Think of eligibility like a checklist at a doctor’s office. Having one box checked isn’t enough. The more boxes you check, the stronger your position.
| Requirement | Standard | Notes |
|---|---|---|
| Drug Type | Injectable Depo-Provera | Not the subcutaneous version |
| Minimum Duration | Approximately 12 months | Longer use strengthens claim |
| Medical Diagnosis | Meningioma confirmed by MRI, CT, or biopsy | Medical records required |
| Treatment Required | Surgery, radiation, or active monitoring | Severity matters |
| Timing | Diagnosis after Depo-Provera use began | Causal sequence must be plausible |
| Documentation | Pharmacy records, medical records | Both strongly preferred |
Women who cannot locate pharmacy records can sometimes use prescription records from their doctor’s office, insurance EOB documents, or medical history notes confirming the injections.
Key Takeaway: Strong documentation of both your Depo-Provera use and your meningioma diagnosis is the foundation of a credible claim.
Depo-Provera Settlement Amount 2026: What to Expect
No global settlement has been announced in the Depo-Provera lawsuit as of 2026. Cases are still in the litigation phase, and settlement amounts are not yet finalized.
That said, legal analysts and trial attorneys working these cases have offered projections. Those projections are based on the severity of harm, the strength of the science, and comparable pharmaceutical settlements from similar cases.
Looking at cases like the NuvaRing MDL and the Essure settlements, women with high-severity injuries in cases with strong scientific backing have historically received settlements ranging from the low tens of thousands to well over $100,000.
| Projected Settlement Tiers (Estimated, Not Guaranteed) | Range |
|---|---|
| Tier 1: Minor tumor, no surgery | $15,000 to $50,000 |
| Tier 2: Surgery required, partial recovery | $75,000 to $200,000 |
| Tier 3: Surgery plus radiation, significant disability | $200,000 to $500,000+ |
| Tier 4: Catastrophic injury or death | Potentially $1 million+ |
These figures are illustrative projections drawn from comparable litigation. Actual settlement values will depend on case-specific facts, bellwether trial outcomes, and negotiation dynamics.
How Much Is the Depo-Provera Lawsuit Payout Per Person?
The individual payout per person in the Depo-Provera lawsuit will vary significantly depending on the facts of each case. There is no flat payment amount applied to every plaintiff.
Factors that directly influence individual payout size include the duration of drug use, severity of the meningioma, whether surgery was performed, recovery outcomes, lost wages, and the quality of the plaintiff’s documentation.
A woman who used Depo-Provera for eight years, developed a large meningioma, underwent two surgeries, and suffered permanent neurological damage would likely receive far more than a woman who used the drug for one year and had a small tumor removed without complications.
Key factors affecting payout size:
- Total years of Depo-Provera use (longer use, stronger claim)
- Grade and size of meningioma at diagnosis
- Whether surgery, radiation, or both were required
- Permanent neurological damage or disability
- Lost income and career impact
- Pain and suffering documentation
- Strength of medical and pharmacy records
Attorney contingency fees typically range from 33 to 40 percent of any recovery in mass tort cases.
Depo-Provera Long-Term Side Effects Behind the Claims
The long-term side effects of Depo-Provera that are driving the most serious legal claims center on meningioma development from prolonged exposure to medroxyprogesterone acetate.
Beyond brain tumors, the drug has a documented history of other long-term concerns. These include significant bone density loss with extended use, a side effect the FDA actually flagged with a black box warning years ago.
The meningioma risk, however, is what propelled this case into mass tort territory. It’s a serious, potentially life-threatening injury that takes years to develop, making it especially difficult for patients to trace back to their contraceptive.
Documented long-term side effects linked to Depo-Provera:
- Meningioma brain tumors (primary lawsuit basis)
- Bone mineral density loss (FDA black box warning issued)
- Prolonged fertility delays after stopping injections
- Irregular bleeding and hormonal disruption
- Depression and mood changes
- Weight gain and metabolic effects
The bone density warning has been on the label since 2004. The meningioma warning was not added until 2024. That 20-year gap is central to the plaintiffs’ case.
Key Takeaway: The 20-year gap between the bone density warning (2004) and the meningioma warning (2024) is one of the most damaging facts for Pfizer in this litigation.
The Meningioma Study That Changed Everything
The scientific turning point in the Depo-Provera lawsuit came in 2023, when France’s national drug safety agency, ANSM, published a major population-based study examining the connection between progestins and meningioma.
The ANSM study examined hundreds of thousands of women over a multi-year observation period. Its findings were stark. Women who used high-dose synthetic progestins, including medroxyprogesterone acetate, faced a substantially elevated risk of developing intracranial meningioma compared to non-users.
The study found that women with five or more years of Depo-Provera use had a meningioma risk more than five times higher than women who had never used the drug. That is not a small margin. That is a statistically significant finding that drove regulatory action.
| ANSM Study Highlights | Data |
|---|---|
| Study Type | Population-based observational study |
| Published | 2023 |
| Key Finding | 5+ year users: over 5x elevated meningioma risk |
| Drug Examined | Medroxyprogesterone acetate and other progestins |
| Regulatory Response | FDA updated Depo-Provera label in 2024 |
The FDA cited this and similar European research when it updated the Depo-Provera label in 2024. That label update was a public acknowledgment that the risk was real. Plaintiffs use it as direct evidence that the warning should have come sooner.
Depo-Provera MDL Consolidation: What It Means for Your Case
The Depo-Provera MDL, or Multidistrict Litigation, is the federal court mechanism used to manage the large number of individual lawsuits filed against Pfizer in a centralized and efficient way.
When hundreds or thousands of people file lawsuits making similar claims against the same defendant, federal courts can consolidate those cases into a single MDL before one judge. In the Depo-Provera litigation, that court is in the Northern District of Illinois.
This does not mean your case merges with everyone else’s into one lawsuit. Think of it more like a coordinated investigation. Your case keeps its individual identity, but pretrial work, such as gathering evidence, deposing experts, and challenging legal theories, happens together.
| MDL Explained | What It Means for You |
|---|---|
| Centralized pretrial proceedings | Faster, more efficient discovery |
| Bellwether test trials | First cases tried to gauge jury reaction |
| Individual cases preserved | Your claim stays yours |
| Settlement negotiations centralized | Global deals negotiated after bellwethers |
| One judge oversees discovery | More consistent rulings |
If bellwether trials produce large plaintiff verdicts, Pfizer is likely to enter serious settlement talks with all remaining plaintiffs.
Key Takeaway: The MDL process means your case is part of a coordinated legal effort, not lost in a crowd. Individual claims remain active throughout.
Depo-Provera Class Action vs. Mass Tort: Key Differences
The Depo-Provera litigation is technically a mass tort MDL, not a traditional class action. Understanding this difference can change how you think about your claim.
In a true class action, one or more lead plaintiffs represent an entire group. Every member of the class gets the same settlement regardless of individual circumstances. That works well for cases involving relatively uniform harm, like a data breach where everyone loses the same type of information.
Mass tort MDL cases, like Depo-Provera, involve individualized injuries. No two plaintiffs have identical medical histories, tumor grades, or treatment outcomes. So individual cases are handled based on their unique facts.
| Feature | Class Action | Mass Tort MDL |
|---|---|---|
| One settlement for all | Yes | No |
| Individual facts considered | No | Yes |
| Payout varies per plaintiff | No | Yes |
| Lead plaintiff represents group | Yes | No |
| Best for uniform harm | Yes | No |
| Best for personal injury | No | Yes |
For Depo-Provera plaintiffs, the mass tort structure is more favorable. Your individual injury level, treatment costs, and long-term effects are taken into account separately.
How to File a Depo-Provera Lawsuit Claim in 2026
Filing a Depo-Provera lawsuit claim in 2026 starts with contacting a mass tort attorney who is actively working these cases. You do not file directly with the court on your own.
Most attorneys handling Depo-Provera claims work on a contingency fee basis. That means you pay nothing upfront. The attorney receives a percentage of your recovery only if you win or settle.
Once you contact an attorney, the typical intake process works like this:
Step 1: Initial Consultation
You share your Depo-Provera use history and medical diagnosis details. The attorney evaluates whether your case meets the core criteria.
Step 2: Document Collection
Your attorney helps gather pharmacy records, medical records, imaging results, and surgical records. This is the evidence base for your claim.
Step 3: Case Evaluation
The law firm reviews the strength of your case, assigns it to the appropriate tier, and files a complaint in federal court.
Step 4: MDL Enrollment
Your individual case is transferred to the Northern District of Illinois MDL.
Step 5: Pretrial Process
Your case proceeds through discovery alongside thousands of others, with bellwether trials setting the tone for resolution.
Documents to gather now:
- Pharmacy prescription records for Depo-Provera
- Doctor’s office records confirming injections
- Insurance Explanation of Benefits documents
- MRI, CT, or biopsy results confirming meningioma
- Surgical reports and radiation treatment records
Key Takeaway: Filing starts with a free consultation with a mass tort attorney. The process is largely handled for you once you provide documents and sign a retainer agreement.
Depo-Provera Statute of Limitations: Don’t Miss Your Window
The statute of limitations for Depo-Provera lawsuits varies by state, but most states allow two to three years from the date of diagnosis or the date you knew, or should have known, the drug caused your injury.
This “discovery rule” is important. Many women were diagnosed with meningioma years before the Depo-Provera connection became widely known. In those cases, the clock may have started running only recently.
Missing the statute of limitations means your claim is barred forever, regardless of how strong your medical evidence is. Time is not on your side in this type of litigation.
| State Statute of Limitations Examples | Timeframe |
|---|---|
| California | 2 years from discovery |
| New York | 2.5 years from injury or discovery |
| Texas | 2 years from discovery |
| Florida | 2 years from discovery |
| Illinois | 2 years from injury or discovery |
| Federal (general guidance) | Varies; typically 2 to 3 years |
These are general figures. Your state’s exact rules should be confirmed by your attorney.
If you received a meningioma diagnosis within the last three years and used Depo-Provera, you should speak with an attorney as soon as possible. Waiting has no benefit and carries real legal risk.
Depo-Provera Lawsuit Update and News for 2026
The most significant development in the Depo-Provera lawsuit heading into 2026 is the continued growth of the MDL and the approaching bellwether trials that will test the case’s core theories before real juries.
In late 2025 and early 2026, the court overseeing the MDL began the process of selecting bellwether cases. These are representative plaintiffs whose cases will go to trial first.
The outcomes of these early trials will tell both sides a great deal. Strong plaintiff verdicts put pressure on Pfizer to settle. Defense wins could slow settlement negotiations significantly.
2026 Key Developments:
- MDL case count surpassed 10,000 filed claims (projected)
- Bellwether case selection actively underway
- FDA label warning (added in 2024) being used as evidence in discovery
- International regulatory actions in France and the EU being cited in U.S. proceedings
- Pfizer has not announced any settlement fund or global resolution
The absence of a settlement announcement in 2026 is not unusual at this stage. Most major pharmaceutical MDLs take five to seven years from filing to final resolution. Patience is required.
How Long Does the Depo-Provera Lawsuit Take?
Most plaintiffs in a mass tort MDL like the Depo-Provera case can expect the legal process to take three to seven years from the time they file their individual claim to the time they receive a payment.
That’s a long time. But it is normal for pharmaceutical litigation of this scale. The sheer volume of cases, the complexity of medical evidence, and the number of parties involved all slow the process.
Here is how the typical MDL timeline breaks down:
| Phase | Typical Duration |
|---|---|
| Intake and Filing | 1 to 3 months |
| MDL Enrollment | 1 to 6 months |
| Discovery Phase | 1 to 2 years |
| Bellwether Trials | 2 to 3 years into MDL |
| Settlement Negotiations | 6 to 18 months after bellwethers |
| Payment Distribution | 6 to 12 months after settlement |
| Total Estimated Timeline | 3 to 7 years from filing |
Women who filed in 2024 or early 2025 may see resolution in 2027 to 2030, depending on how bellwether trials go and how quickly Pfizer moves toward settlement.
Key Takeaway: This is not a quick process. But filing now preserves your rights and puts you in line for a settlement when it does happen.
Is Depo-Provera Still on the Market?
Yes, Depo-Provera is still on the market as of 2026. The FDA did not pull the drug from sale. Instead, it updated the label in 2024 to include a warning about meningioma risk.
This approach, keeping a drug available while adding a warning, is typical for the FDA when scientific evidence identifies a risk but the drug still has therapeutic value for some patients.
Women who are currently using Depo-Provera should speak with their healthcare provider about the updated risks. Existing prescriptions are still being filled at pharmacies across the country.
The ongoing availability of the drug does not weaken the lawsuit. It actually supports plaintiff arguments that Pfizer continues to profit from the drug while women remain exposed to an inadequately disclosed risk.
| Depo-Provera Market Status 2026 | Details |
|---|---|
| Available for Prescription | Yes |
| FDA Pull from Market | No |
| Updated Label | Yes, in 2024 (meningioma warning added) |
| Generic Versions Available | Yes |
| Countries with Stricter Restrictions | France, some EU nations |
France placed more aggressive restrictions on high-dose progestins after the ANSM study. The U.S. has taken a less restrictive approach so far.
Frequently Asked Questions
Who qualifies for the Depo-Provera class action lawsuit?
Women who used Depo-Provera injections for at least 12 months and were diagnosed with a meningioma brain tumor are the core candidates.
Stronger claims involve longer use periods, surgery or radiation treatment, and solid documentation of both the drug use and the diagnosis.
Claims with five or more years of use and a confirmed meningioma diagnosis are considered the highest priority by most mass tort firms.
How much money can I get from the Depo-Provera lawsuit settlement?
No guaranteed payout amounts have been announced, but projected ranges based on comparable cases run from $15,000 to over $500,000 depending on injury severity.
Women who required surgery, experienced permanent neurological damage, or lost significant income are likely to see higher individual payouts.
Attorney fees typically reduce the net recovery by 33 to 40 percent under standard contingency arrangements.
What is the deadline to file a Depo-Provera lawsuit claim in 2026?
The deadline depends on your state’s statute of limitations, which is typically two to three years from your meningioma diagnosis or from when you connected it to Depo-Provera.
If you were diagnosed in the last two years, you may still be within your filing window.
Speaking with a mass tort attorney immediately is the only way to confirm your specific deadline.
What is the difference between the Depo-Provera class action and the MDL?
The Depo-Provera litigation is technically an MDL, not a traditional class action. In an MDL, each plaintiff retains an individual case with facts and compensation evaluated separately.
In a traditional class action, all members receive the same payout regardless of their personal circumstances.
The MDL structure benefits Depo-Provera plaintiffs because it accounts for how seriously each person was harmed.
Can I still sue if I stopped using Depo-Provera years ago?
Yes, you can still file a claim if you stopped using Depo-Provera years ago, as long as you were later diagnosed with a meningioma.
The statute of limitations clock typically starts from the date of your meningioma diagnosis or from the date you reasonably discovered the connection to the drug.
Women who stopped using the drug in the 2010s but received a meningioma diagnosis after 2022 may still be within their legal window.
What You Should Do Right Now
The Depo-Provera case is moving. Bellwether trials are coming. And every state’s statute of limitations is ticking.
If you used Depo-Provera and received a meningioma diagnosis, start pulling together your medical records and pharmacy history now. That documentation is the foundation of your claim.
Contact a mass tort attorney for a free consultation. You won’t pay anything upfront. But waiting too long could cost you the right to file entirely.
